Identifying Key Circulating Tumor DNA Parameters for Predicting Clinical Outcomes in Metastatic Non-Squamous Non-Small Cell Lung Cancer After First-Line Chemoimmunotherapy

Utilizing longitudinal ctDNA data from the large phase 3 IMpower150 study of atezolizumab in combination with chemotherapy with or without bevacizumab in patients with stage IV non-squamous Non-Small Cell Lung Cancer, researchers reported that post-treatment ctDNA response correlates significantly with radiographic response.